Search Results - "Sznol, Joshua A"

Studies of NVP-BEZ235 in melanoma by Sznol, Joshua A, Jilaveanu, Lucia B, Kluger, Harriet M

“…The PI3k pathway represents an attractive target for drug development in melanoma, as numerous studies have shown that this pathway is active in malignant…”
Get more information

Routine post-operative labs and healthcare system burden in acute appendicitis by Sznol, Joshua A., Becher, Robert, Maung, Adrian A., Bhattacharya, Bishwajit, Davis, Kimberly, Schuster, Kevin M.

“…Data from the National Health Expenditure Accounts have shown a steady increase in healthcare cost paralleled by availability of laboratory tests. Resource…”
Get full text

Expression of drug targets in primary and matched metastatic renal cell carcinoma tumors by Aziz, Saadia A, Sznol, Joshua A, Adeniran, Adebowale, Parisi, Fabio, Kluger, Yuval, Camp, Robert L, Kluger, Harriet M

“…Targeted therapies in renal cell carcinoma can have different effects on primary and metastatic tumors. To pave the way for predictive biomarker development,…”
Get full text

Management and Outcome of High-Grade Hepatic and Splenic Injuries by Presser, Elise, Sznol, Joshua A., Schuster, Kevin M.

“…Purpose of Review Hepatic and splenic injuries are commonly found in patients who experience trauma and result in significant morbidity and mortality…”
Get full text

Association Between American Board of Surgery In-Training Examination Scores and Resident Performance by Ray, Juliet J, Sznol, Joshua A, Teisch, Laura F, Meizoso, Jonathan P, Allen, Casey J, Namias, Nicholas, Pizano, Louis R, Sleeman, Danny, Spector, Seth A, Schulman, Carl I

“…The American Board of Surgery In-Training Examination (ABSITE) is designed to measure progress, applied medical knowledge, and clinical management; results may…”
Get more information

Etiology of fatal thoracic aortic injuries: Secondary data analysis by Sznol, Joshua A., Koru-Sengul, Tulay, Graygo, Jill, Murakhovsky, Denis, Bahouth, George, Schulman, Carl I.

“…Objectives: Motor vehicle crashes remain a leading cause of death in the United States (US). Thoracic aortic dissection due to blunt trauma remains a major…”
Get full text

Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma by Aziz, Saadia A, Sznol, Joshua A, Albiges, Laurence, Zito, Christopher, Jilaveanu, Lucia B, Camp, Robert L, Escudier, Bernard, Kluger, Harriet M

“…Sorafenib was the first Food and Drug Administration approved anti-angiogenic therapy for renal cell carcinoma (RCC). Currently, there are no validated…”
Get full text